Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
Entera Bio reported robust preclinical data at ENDO 2026 for EB612, an oral peptide for hypoparathyroidism, and EB618, an oral GLP-1/glucagon agonist for obesity. EB612 demonstrated sustained calcium increases and bioavailability across multiple animal models, supporting a planned IND submission in late 2026, while EB618 showed dose-proportional pharmacokinetics in primates.
Key figures
- Drug Name
- EB612, EB618
- Phase Of Trial
- Preclinical
- Eb613 phase 2 n
- 161
- Eb612 ind timeline
- late 2026
- Eb618 safety margin
- >10x clinical dose
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.